Fig. 2From: Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumoursA Progression Free Survival curve. B Overall Survival curve. Legend: Progression free survival (PFS) and overall survival (OS) of each enrolled patient (n = 26) in the cohort “Durvalumab for dMMR/MSI-H tumours”. Kaplan-Meier curves for estimated PFS (A) and OS (B), with 95% Confidence Intervals (dashed lines)Back to article page